iBio logo
iBio IBIO
$ 1.19 1.24%
report update icon

Quarterly report 2026-Q4
added 08-28-2026

iBio Cash Flow 2026-2010 | IBIO

Brief cash flow overview of iBio

Cash flows are assessed across five available annual periods spanning 2021 to 2025.

Operating cash flow is negative at -$15.3 million, leaving internal funding capacity weak.

Only 0 of five annual observations were positive, indicating weak repeatability.

Conclusion

Taken together, iBio's cash flow indicators point to increased dependence on reserves or outside financing.

Annual Cash Flow iBio

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Operating Cash Flow

-23.2 M -15.3 M -18.6 M -30.4 M -37.5 M -30.1 M -13.3 M -14 M -13.5 M -13.2 M - - - -4.85 M -6.01 M -5.34 M -

Depreciation & Amortization

558 K 484 K 638 K 674 K 2.28 M 472 K 282 K 179 K 1.37 M 1.33 M 577 K 5 K 3 K 2 K 330 K 377 K -

Accounts Payables

4.42 M 2.19 M 358 K 1.85 M 4.26 M 2.25 M 1.76 M 1 M 790 K 749 K 1.18 M 1.1 M 297 K 2.4 M 2.85 M - -

Accounts Receivables

- - - - 1 M 426 K 75 K 97 K 75 K 175 K 484 K 445 K 205 K 1.01 M 351 K - -

Total Inventories

- - - - 3.9 M 27 K - - - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow iBio

2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- -17 M -10.9 M -5.66 M - -5.66 M - - - -3.72 M - - - -5.34 M - - - -14 M -21.6 M - - -9.35 M -20 M - - -7.07 M -15.5 M -7.07 M - -2.29 M -5.69 M -2.29 M - -778 K -5.45 M -778 K - -3.02 M -6.6 M -3.02 M - -2.27 M - - - - - - - - - - - -911 K 2.2 M - - -1.29 M -2.69 M -1.29 M - -1.23 M -2.01 M -1.23 M

Depreciation & Amortization

- 411 K 264 K 123 K 5 K 123 K - 5 K 5 K 120 K - 5 K 5 K 165 K - 5 K 49 K 271 K 388 K 122 K 123 K 306 K 823 K 119 K 114 K 97 K 114 K 97 K 71 K 66 K 137 K 66 K 179 K 179 K 179 K 360 K 341 K 338 K 340 K 338 K 326 K 324 K 326 K 324 K 1 K 1 K 2 K 1 K 90 K 1 K 2 K 1 K 88 K 1 K 1 K 1 K 83 K 82.4 K 166 K 82 K 80 K 80 K 161 K 80 K

Accounts Payables

2.19 M 3.04 M 2.65 M 2.82 M 2.65 M 2.82 M 2.19 M 1.48 M 614 K 855 K 358 K 1.23 M 1.86 M 1.91 M 1.85 M 2.01 M 4 M 4.81 M 4.26 M 5.28 M 2.74 M 2.29 M 2.25 M 2.25 M 2.41 M 1.6 M 1.76 M 1.76 M 442 K 661 K 1 M 1 M 662 K 692 K 790 K 790 K 701 K 596 K 749 K 749 K 731 K 979 K 1.18 M 1.18 M 1.33 M 1.27 M 1.1 M 1.1 M 984 K 516 K 297 K 297 K 1.24 M 1.31 M 2.4 M 2.4 M 2.71 M 2.42 M 2.85 M 2.85 M 4.04 M 2.98 M 2.9 M 2.9 M

Accounts Receivables

- - - 65 K - 65 K - - - - - - - - - 70 K 970 K 1.06 M 1 M 1 M 111 K 207 K 426 K 426 K 180 K 300 K 75 K 75 K 224 K 75 K 97 K 97 K 155 K 119 K 75 K 75 K 136 K 260 K 175 K 175 K 25 K 170 K 484 K 484 K 202 K 480 K 445 K 445 K 584 K - 205 K 205 K 1.01 M 1.01 M 1.01 M 1.01 M 390 K 390 K 351 K 351 K 234 K 320 K 344 K 344 K

Total Inventories

- - - - - - - - - - - - - - - - - - - 3.28 M 1.99 M 587 K 27 K 27 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company iBio, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
AbbVie AbbVie
ABBV
$ 263.04 0.49 % $ 465 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 11.41 2.15 % $ 3.41 B canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 5.53 6.02 % $ 678 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.09 3.74 % $ 139 M schweizSchweiz
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
$ 8.61 0.16 % $ 2.05 B usaUSA
Eiger BioPharmaceuticals Eiger BioPharmaceuticals
EIGR
- -9.21 % $ 2.55 M usaUSA
89bio 89bio
ETNB
- - $ 1.55 B usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
- - $ 1.41 B canadaCanada
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Genocea Biosciences Genocea Biosciences
GNCA
- -15.0 % $ 3.04 M usaUSA
Gritstone Oncology Gritstone Oncology
GRTS
- 0.42 % $ 213 M usaUSA
G1 Therapeutics G1 Therapeutics
GTHX
- - $ 370 M usaUSA
Harpoon Therapeutics Harpoon Therapeutics
HARP
- - $ 763 M usaUSA
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
HOOKIPA Pharma HOOKIPA Pharma
HOOK
- -6.92 % $ 79.4 M usaUSA
Intercept Pharmaceuticals Intercept Pharmaceuticals
ICPT
- - $ 643 M usaUSA
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Intra-Cellular Therapies Intra-Cellular Therapies
ITCI
- - $ 13.6 B usaUSA
Kinnate Biopharma Kinnate Biopharma
KNTE
- - $ 123 M usaUSA
Chinook Therapeutics Chinook Therapeutics
KDNY
- - $ 2.6 B usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
- -3.69 % $ 12.4 M usaUSA
Kronos Bio Kronos Bio
KRON
- 1.49 % $ 50.8 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
La Jolla Pharmaceutical Company La Jolla Pharmaceutical Company
LJPC
- - $ 154 M usaUSA
LogicBio Therapeutics LogicBio Therapeutics
LOGC
- - $ 229 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Merrimack Pharmaceuticals Merrimack Pharmaceuticals
MACK
- - $ 216 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
Mirati Therapeutics Mirati Therapeutics
MRTX
- - $ 3.3 B usaUSA
NexImmune NexImmune
NEXI
- 70.13 % $ 4.12 M usaUSA
9 Meters Biopharma 9 Meters Biopharma
NMTR
- -42.97 % $ 1.05 M usaUSA
InVivo Therapeutics Holdings Corp. InVivo Therapeutics Holdings Corp.
NVIV
- -37.48 % $ 476 K usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
ObsEva SA ObsEva SA
OBSV
- -15.52 % $ 10.5 M schweizSchweiz
Oncorus Oncorus
ONCR
- -8.54 % $ 3.19 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA
Oncternal Therapeutics Oncternal Therapeutics
ONCT
- -24.12 % $ 1.56 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Orchard Therapeutics plc Orchard Therapeutics plc
ORTX
- 1.02 % $ 90.8 M britainBritain